Last reviewed · How we verify
NCT04161287
Comparison of Efficacy in SBRT of HCC ≤5 cm With or Without TACE
trial testing transcatheter arterial chemoembolization in Small Hepatocellular Carcinoma in 330 participants. Status unknown.
11 December 2023
Quick facts
| Lead sponsor | Beijing 302 Hospital |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 330 |
| Start date | 11 October 2019 |
| Primary completion | 11 December 2023 |
| Estimated completion | 11 January 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- transcatheter arterial chemoembolization — full drug profile →
Conditions studied
- Small Hepatocellular Carcinoma — all drugs for Small Hepatocellular Carcinoma →
- Stereotactic Body Radiation Therapy — all drugs for Stereotactic Body Radiation Therapy →
- Transcatheter Arterial Chemoembolization — all drugs for Transcatheter Arterial Chemoembolization →
Sponsor
Beijing 302 Hospital
Who can join
Adults 30 to 80, any sex, with Small Hepatocellular Carcinoma or Stereotactic Body Radiation Therapy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The study aims to compare efficacy and adverse reactions of hepatocellular carcinoma participants (≤5cm) who receive stereotactic body radiation therapy with or without transcatheter arterial chemoembolization.The investigators will optimize the combined treatment schedule of SBRT for hepatocellular carcinoma participants by comparing overall survival rates, progression-free survival rates and local control and adverse reaction occurrence rates in the two groups.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
The role of stereotactic body radiotherapy in hepatocellular carcinoma: guidelines and evidences.
Hu Y, Zhao C, Ji R, Chen W, et al · · 2022 · cited 10× · PMID 39036452 · DOI 10.1016/j.jncc.2022.05.002
Verify or expand the search:
- PubMed search for NCT04161287
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of transcatheter arterial chemoembolization
Trials testing the same drug.
- NCT05352204 — Effect of Tumor Micronecrosis on Postoperative Transcatheter Arterial Chemoembolization in Patients With Hepatocellular · completed
Other Beijing 302 Hospital trials
Trials by the same sponsor.
- NCT07514832 — VA-CIG Regimen for Previously Untreated Acute Myeloid Leukemia: A Multicenter Prospective Single-Arm Trial · Phase 2 · recruiting
- NCT07297173 — Phase 1 Study of Chemotherapy Plus HLA-mismatched GPBMC Infusion Bridging to Allo-HSCT for R/R Leukemia · Phase 1 · recruiting
- NCT06556862 — Exploration of Dalpiciclib Plus HDACi in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor · Phase 2 · not yet recruiting
- NCT07106658 — TEAS for Variceal Bleeding Endoscopy in Cirrhosis · NA · completed
- NCT06926647 — A Real-World Study of Antiviral Therapy in Children With Chronic Hepatitis B · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04161287 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Beijing 302 Hospital
- Last refreshed: 2 February 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04161287.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing